Oral sumatriptan and almotriptan-delimiting the maoi effect
Headache: The Journal of Head and Face Pain, 04/24/2012Oberhardt F et al.
A model for oral sumatriptan pharmacokinetics can be found using the differential calculus, and it is generalizable to oral almotriptan. The model suggests that an MAOI–A probably has greater effect on elimination kinetics than first–pass metabolism, and that this interaction appears to be overstated in product labeling.
Extension of a previous model for subcutaneous sumatriptan.
Numerical solutions to 3 concurrent differential equations were found, with prospective criteria for model acceptance based upon comparison with clinically observed data.
The model was successfully extended by inserting a time factor into the absorption phase.
This extension was robust: it imitated clinical data for 3 oral sumatriptan dose sizes (both without and with a concomitant MAOI–A) and also for oral almotriptan.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.